US2016120878A1PendingUtilityA1
Derivatives of betulin
Est. expiryDec 16, 2031(~5.4 yrs left)· nominal 20-yr term from priority
A61P 31/00A61P 31/12A61P 31/18C07C 219/24A61K 31/56C07C 219/06C07D 205/04C07C 233/33C07C 215/08C07J 63/008A61K 31/568C07D 413/06A61K 31/44C07C 211/38C07C 211/10C07J 53/002A61K 31/40A61K 31/551A61K 31/54A61K 31/58A61K 31/222A61K 31/4985C07D 239/48A61K 31/495C07D 243/08C07C 2603/52A61K 31/505C07D 265/30A61K 31/397C07C 69/34A61K 45/06C07D 213/40C07C 2601/02A61K 31/506C07D 498/14C07C 225/14C07C 211/04A61K 31/225C07D 265/32C07D 207/09C07C 2601/14C07C 217/26C07D 217/04C07D 239/26A61K 31/5375A61K 31/472
53
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to compounds characterized by having a structure according to the following formula I: or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.
Claims
exact text as granted — not AI-modified1 . A compound having the structure of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
A is
L 1 and L 2 are independently selected from a bond or [C(R 6 R 6 ′)] q ;
each instance of Q is independently selected from —CH 2 — or —C(═O)—;
W is selected from a bond or O;
R 1 is selected from the group consisting of —H, (C 1 -C 12 )alkyl, —C(O)R 5 , —CH 2 —O—(C 1 -C 6 )alkyl, 2-tetrahydro-2H-pyran, and
R 2 is selected from the group consisting of —H, (C 1 -C 12 )alkyl, —(C 1 -C 6 )alkyl-OR 4 , —(C 1 -C 6 )alkyl-O—(C 1 -C 6 )alkyl, —C(O)R 5 , —(CH 2 ) r NR 7 R 8 , and —(CH 2 ) r N + (R 4 ) 3 , wherein when W is O, R 1 and R 2 can optionally be taken together with the O and N to which they are respectively joined to form a 4 to 8 membered heterocyclyl ring, wherein the heterocyclyl ring may be optionally substituted by one to two R 11 groups;
R 3 is selected from the group consisting of hydrogen, (C 1 -C 12 )alkyl, NR 1 R 2 , —OR 5 ,
wherein:
X is a monocyclic or bicyclic (C 5 -C 14 )aryl;
Y is selected from a monocyclic or bicyclic (C 2 -C 9 )heterocyclyl or monocylic or bicyclic (C 2 -C 9 )heteroaryl, each having one to three heteroatoms selected from S, N or O;
Z is a monocyclic or bicyclic (C 3 -C 8 )cycloalkyl;
R 2 and R 3 can optionally be taken together with the nitrogen and L 2 to which they are respectively joined to form a 4 to 8 membered heterocyclyl ring, wherein the heterocyclyl ring may be optionally substituted by one to two R 11 groups;
R 4 is selected from the group consisting of —H and (C 1 -C 6 )alkyl;
R 5 is selected from the group consisting of —H, (C 1 -C 6 )alkyl, —R 3 , —(CH 2 ) r NR 7 R 8 , and —(CH 2 ) r OR 7 ;
R 6 and R 6 ′ are independently selected from the group consisting of H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkoxy, haloalkyl, —Y, —(CH 2 ) r NR 7 R 8 , —C(O)OH, and —C(O)NH 2 , wherein the R 6 and R 6 ′ groups can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyl ring, and wherein the cycloalkyl ring may be optionally substituted by one to three R 11 groups;
R 7 and R 8 are independently selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, -Q-aryl-(R) n , —NR 14 R 15 , —C(O)CH 3 , wherein R 7 and R 8 can optionally be taken together with the nitrogen to which they are joined to form a 4 to 8 membered heterocyclyl or heteroaryl ring containing one to three heteroatoms selected from —NR 5 —, —O—, —S—, —S(O)—, or —SO 2 —, wherein the heterocyclyl or heteroaryl ring may be optionally substituted by one to three R 11 groups;
R 9 is halo;
R 10 is —N(R 16 ) 2 ;
R 11 , R 12 , and R 13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C 1 -C 6 )alkoxy, —R 6 (R 9 ) q , —OR 6 (R 9 ) q , nitro, —SO 2 R 6 , (C 1 -C 6 )alkyl, —C(O)R 10 , —R 4 YR 6 , —CO(O)R 4 , and —CO(O)R 5 , wherein any two R 11 , R 12 or R 13 groups can optionally join to form a 3 to 8 membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring, wherein the heterocyclyl or heteroaryl ring may contain one to three heteroatoms selected from —NR 5 —, —O—, —S—, —S(O)—, or —SO 2 —, and wherein the cycloalkyl, aryl, heterocyclyl or heteroaryl ring may be optionally substituted by one to three R 16 groups;
R 14 and R 15 are independently selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkoxy, —[C(R 6 ) 2 ] r —, —O[C(R 6 ) 2 ] r —, oxo, hydroxyl, halo, —C(O)R 7 , —R 10 , and —CO(O)R 2 , wherein R 14 and R 15 can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyl ring or 4 to 8 membered heterocyclyl ring containing one to three heteroatoms selected from —NR 5 —, —O—, —S—, —S(O)—, or —SO 2 —, wherein the cycloalkyl ring or heterocyclyl ring may be optionally substituted by one to three R 16 groups;
R 16 is independently selected from the group consisting of —H, halo, oxo, hydroxyl, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, —R 6 (R 9 ) q , —OR 6 (R 9 ) q , —N(R 4 ) 2 , —(CH 2 ) r -heterocyclyl, —C(O)OH, —C(O)NH 2 , —R 5 (R 9 ) q , —OR 5 (R 9 ) q , nitro, —SO 2 R 6 , —C(O)R 16 , and —CO(O)R 4 ;
m and n in each instance are independently 0, 1, 2, 3, or 4;
p is independently 0, 1, 2, 3, or 4; and
r and q in each instance are independently 0, 1, 2, 3, or 4.
2 . The compound of claim 1 , wherein L 1 and L 2 are both [C(R 6 R 6 ′)] q .
3 . The compound of claim 1 , wherein L 1 and L 2 are both —CH 2 —.
4 . The compound of claim 1 , wherein each instance of q is independently 1, 2, or 3.
5 . The compound of claim 1 , wherein q is 1.
6 . The compound of claim 1 , wherein W is O.
7 . The compound of claim 1 , wherein W is a bond.
8 . The compound of claim 1 , wherein when W is a bond, then R 1 is —H.
9 . The compound of claim 1 , wherein when W is O, then R 1 is —H.
10 . The compound of claim 1 , wherein Q m in the A group is absent and in the A group is —CH 2 — and the Q in the Formula I structure is —C(═O)—.
11 . The compound of claim 1 , wherein R 1 is —H.
12 . The compound of claim 1 , wherein R 2 is —(CH 2 ) r NR 7 R 8 .
13 . The compound of claim 1 , wherein R 2 is (dimethylamino)ethyl.
14 . The compound of claim 1 , wherein each instance of r is independently 0, 1, 2, or 3.
15 . The compound of claim 1 , wherein r is 2.
16 . The compound of claim 1 , wherein R 3 is
17 . The compound of claim 1 , wherein X is a monocyclic (C 5 -C 14 )aryl.
18 . The compound of claim 1 , wherein X is phenyl.
19 . The compound of claim 1 , wherein R 4 is —H.
20 . The compound of claim 1 , wherein each instance of m is independently 0 or 1.
21 . The compound of claim 1 , wherein m is 0.
22 . The compound of claim 1 , wherein m is 1.
23 . The compound of claim 1 , wherein n is 1.
24 . The compound of claim 1 , wherein R 6 and R 6 ′ are both —H.
25 . The compound of claim 1 , wherein R 7 and R 8 are both (C 1 -C 6 )alkyl.
26 . The compound of claim 1 , wherein R 7 is methyl.
27 . The compound of claim 1 , wherein R 8 is methyl.
28 . The compound of claim 1 , wherein R 7 and R 8 are both methyl.
29 . The compound of claim 1 , wherein R 11 is halo.
30 . The compound of claim 1 , wherein R 11 is selected from chloro, bromo, or fluoro.
31 . The compound of claim 1 , wherein R 11 is chloro.
32 . The compound of claim 1 , wherein R 11 is absent.
33 . The compound of claim 1 , wherein R 14 and R 15 are both′(C 1 -C 6 )alkyl.
34 . The compound of claim 1 , wherein R 14 and R 15 are both methyl.
35 . The compound of claim 1 , wherein A is
36 . The compound of claim 1 , wherein A is
37 . The compound of claim 1 , wherein A is
38 . The compound of claim 1 , wherein A is
39 . A compound having the structure of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
A is
L 1 and L 2 are [C(R 6 R 6 ′)] q ;
each Q is independently selected from —CH 2 — or —C(═O)—;
W is selected from a bond or O;
R 1 is selected from the group consisting of —H, (C 1 -C 6 )alkyl, —C(O)R 4 , and
R 2 is selected from the group consisting of —H, (C 1 -C 6 )alkyl, —(C 1 -C 6 )alkyl-OR 4 , —(C 1 -C 6 )alkyl-O—(C 1 -C 6 )alkyl, —C(O)R 5 , —(CH 2 ) r NR 7 R 8 , and —(CH 2 ) r N + (R 4 ) 3 ;
R 3 is selected from the group consisting of —H, (C 1 -C 12 )alkyl, —NR 1 R 2 , —OR 5 ,
wherein:
X is a monocyclic or bicyclic (C 5 -C 14 )aryl;
Y is selected from a monocyclic or bicyclic (C 2 -C 9 )heterocyclyl or monocytic or bicyclic (C 2 -C 9 )heteroaryl, each having one to three heteroatoms selected from S, N or O;
Z is a monocyclic or bicyclic (C 3 -C 8 )cycloalkyl;
R 4 is selected from the group consisting of —H and (C 1 -C 6 )alkyl;
R 5 is selected from the group consisting of (C 1 -C 6 )alkyl, —(CH 2 ) r NR 7 R 8 , and —(CH 2 ) r OR 7 ;
R 6 and R 6 ′ are independently selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkoxy, haloalkyl, —(CH 2 ) r NR 7 R 8 , —C(O)OH, and —C(O)NH 2 , wherein the R 6 and R 6 ′ groups can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyl ring, and wherein the cycloalkyl ring may be optionally substituted by one to three R 11 groups;
R 7 and R 8 are independently selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, —NR 14 R 15 , and —C(O)CH 3 ;
R 9 is halo;
R 10 is N(R 16 ) 2 ;
R 11 , R 12 , and R 13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C 1 -C 6 )alkoxy, —R 6 (R 9 ) q , —OR 6 (R 9 ) q , nitro, —SO 2 R 6 , (C 1 -C 6 )alkyl, —C(O)R 10 , —R 4 YR 6 , —CO(O)R 4 , and —CO(O)R 5 ;
R 14 and R 15 are independently selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkoxy, —[C(R 6 ) 2 ] r —, —O[C(R 6 ) 2 ] r —, oxo, hydroxyl, halo, —C(O)R 7 , —R 10 , and —CO(O)R 2 ;
R 16 is independently selected from the group consisting of —H, oxo, halo, hydroxyl, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, —R 6 (R 9 ) q , —OR 6 (R 9 ) q , —N(R 4 ) 2 , —(CH 2 ) r -heterocyclyl, —C(O)OH, —C(O)NH 2 , —R 5 (R 9 ) q , —OR 5 (R 9 ) q , nitro, —SO 2 R 6 , —C(O)R 10 , and —CO(O)R 4 ;
m and n in each instance are independently 0, 1, 2, 3, or 4;
p is independently 0, 1, 2, 3, or 4; and
r and q in each instance are independently 0, 1, 2, 3, or 4.
40 . A compound having the structure of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
A is
L 1 and L 2 are both (—CH 2 —);
Q is —C(═O)—;
W is O;
R 1 is —H;
R 2 is selected from the group consisting of —H, (C 1 -C 6 )alkyl, —(C 1 -C 6 )alkyl-OR 4 , —(C 1 -C 6 )alkyl-O—(C 1 -C 6 )alkyl, —C(O)R 5 , and —(CH 2 ) r NR 7 R 8 ,
R 3 is selected from the group consisting of —H, (C 1 -C 12 )alkyl, —NR 1 R 2 , —OR 5 ,
wherein:
X is a monocyclic or bicyclic (C 5 -C 14 )aryl;
Y is selected from a monocyclic or bicyclic (C 2 -C 9 )heterocyclyl or monocylic or bicyclic (C 2 -C 9 )heteroaryl, each having one to three heteroatoms selected from S, N or O;
Z is a monocyclic or bicyclic (C 3 -C 8 )cycloalkyl;
R 4 is selected from the group consisting of —H and (C 1 -C 6 )alkyl;
R 5 is selected from the group consisting of (C 1 -C 6 )alkyl, —(CH 2 ) r NR 7 R 8 , and —(CH 2 ) r OR 7 ;
R 6 and R 6 ′ are independently selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkoxy, haloalkyl, —(CH 2 ) r NR 7 R 8 , —C(O)OH, and —C(O)NH 2 ;
R 7 and R 8 are independently selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, —NR 14 R 15 , and —C(O)CH 3 ;
R 9 is halo;
R 10 is —N(R 16 ) 2 ;
R 11 , R 12 , and R 13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C 1 -C 6 )alkoxy, —R 6 (R 9 ) q , —OR 8 (R 9 ) q , nitro, —SO 2 R 6 , (C 1 -C 6 )alkyl, —C(O)R 10 , —R 4 YR 6 , —CO(O)R 4 , and —CO(O)R 5 ;
R 14 and R 15 are independently selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkoxy, —[C(R 6 ) 2 ] r —, —O[C(R 6 ) 2 ] r —, oxo, hydroxyl, halo, —C(O)R 7 , —R 10 , and —CO(O)R 2 ;
R 16 is independently selected from the group consisting of —H, oxo, halo, hydroxyl, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, —R 6 (R 9 ) q , —OR 6 (R 9 ) q , —N(R 4 ) 2 , —(CH 2 ) r -heterocyclyl, —C(O)OH, —C(O)NH 2 , —R 5 (R 9 ) q , —OR 5 (R 9 ) q , nitro, —SO 2 R 6 , —C(O)R 10 , and —CO(O)R 4 ;
m and n in each instance are independently 0, 1, or 2;
p is independently 0, 1, or 2; and
r and q in each instance are independently 0, 1, 2, or 3.
41 . A compound having the structure of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
A is
L 1 and L 2 are both (—CH 2 —);
Q is —C(═O)—;
W is O;
R 1 is —H;
R 2 is selected from the group consisting of —H, (C 1 -C 6 )alkyl, —C(O)R 5 , and —(CH 2 ) r NR 7 R 8 ,
R 3 is
wherein X is a monocyclic or bicyclic (C 5 -C 14 )aryl;
R 4 is selected from the group consisting of —H and (C 1 -C 6 )alkyl;
R 5 is selected from the group consisting of (C 1 -C 6 )alkyl, —(CH 2 ) r NR 7 R 8 , and —(CH 2 ) r OR 7 ;
R 6 is selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C— 8 )cycloalkyl, (C 1 -C 6 )alkoxy, haloalkyl, —(CH 2 ) r NR 7 R 8 , —C(O)OH, and —C(O)NH 2 ;
R 7 and R 8 are independently selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, —NR 14 R 15 , and —C(O)CH 3 ;
R 9 is halo;
R 10 is —N(R 16 ) 2 ;
R 11 , R 12 , and R 13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C 1 -C 6 )alkoxy, —R 6 (R 9 ) q , —OR 6 (R 9 ) q , nitro, SO 2 R 6 , (C 1 -C 6 )alkyl, —C(O)R 10 , —CO(O)R 4 , and —CO(O)R 5 ;
R 14 and R 15 are independently selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkoxy, —[C(R 6 ) 2 ] r —, —O[C(R 6 ) 2 ] r —, oxo, hydroxyl, halo, —C(O)R 7 , —R 10 , and —CO(O)R 2 ;
R 16 is independently selected from the group consisting of —H, oxo, halo, hydroxyl, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, —R 6 (R 9 ) q , —OR 6 (R 9 ) q , —N(R 4 ) 2 , —(CH 2 ) r -heterocyclyl, —C(O)OH, —C(O)NH 2 , —R 5 (R 9 ) q , —OR 5 (R 9 ) q , nitro, —SO 2 R 6 , —C(O)R 10 , and —CO(O)R 4 ;
m and n in each instance are independently 0, 1, or 2;
p is independently 0, 1, or 2; and
r and q in each instance are independently 0, 1, 2, or 3.
42 . A compound having the structure of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
A is
L 1 and L 2 are both (—CH 2 —);
Q is —C(═O)—;
W is O;
R 1 is —H;
R 2 is —(CH 2 ) r NR 7 R 8 ;
R 3 is
wherein X is phenyl;
R 7 and R 8 are independently selected from the group consisting of —H and methyl;
R 9 is selected from the group consisting of chloro, bromo, and fluoro;
R 11 is selected from the group consisting of chloro, bromo, and fluoro;
m is independently 0, 1, or 2; and
r is independently 1, 2, or 3.
43 . A compound having the structure of Formula (II):
or a pharmaceutically acceptable salt thereof, wherein:
A is
L 1 and L 2 are independently selected from a bond or [C(R 6 R 6 ′)] q ;
each instance of Q is independently selected from —CH 2 — or —C(═O)—;
W is selected from a bond or O;
R 1 is selected from the group consisting of —H, (C 1 -C 12 )alkyl, —C(O)R 5 , —CH 2 —O—(C 1 -C 6 )alkyl, 2-tetrahydro-2H-pyran, and
R 2 is selected from the group consisting of —H, (C 1 -C 12 )alkyl, —(C 1 -C 6 )alkyl-OR 4 , —(C 1 -C 6 )alkyl-O—(C 1 -C 6 )alkyl, —C(O)R 5 , —(CH 2 ) r NR 7 R 8 , and —(CH 2 ) r N + (R 4 ) 3 , wherein when W is O, R 1 and R 2 can optionally be taken together with the O and N to which they are respectively joined to form a 4 to 8 membered heterocyclyl ring, wherein the heterocyclyl ring may be optionally substituted by one to two R 11 groups;
R 3 is selected from the group consisting of —H, (C 1 -C 12 )alkyl, —NR 1 R 2 , —OR 5 ,
wherein:
X is a monocyclic or bicyclic (C 5 -C 14 )aryl, Y is selected from a monocyclic or bicyclic (C 2 -C 9 )heterocyclyl or monocylic or bicyclic (C 2 -C 9 )heteroaryl, each having one to three heteroatoms selected from S, N or O; Z is a monocyclic or bicyclic (C 3 -C 8 )cycloalkyl;
R 2 and R 3 can optionally be taken together with the nitrogen and L 2 to which they are respectively joined to form a 4 to 8 membered heterocyclyl ring, wherein the heterocyclyl ring may be optionally substituted by one to two R 11 groups;
R 4 is selected from the group consisting of —H and (C 1 -C 6 )alkyl;
R 5 is selected from the group consisting of —H, (C 1 -C 6 )alkyl, —R 3 , —(CH 2 ) r NR 7 R 5 , and —(CH 2 ) r OR 7 ;
R 6 and R 6 ′ are independently selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkoxy, haloalkyl, —Y, —(CH 2 ) r NR 7 R 8 , —C(O)OH, and —C(O)NH 2 , wherein the R 6 and R 6 ′ groups can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyl ring, and wherein the cycloalkyl ring may be optionally substituted by one to three R 11 groups;
R 7 and R 8 are independently selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, -Q-aryl-(R 4 ) n , —NR 14 R 15 , —C(O)CH 3 , wherein R 7 and R 8 can optionally be taken together with the nitrogen to which they are joined to form a 4 to 8 membered heterocyclyl or heteroaryl ring containing one to three heteroatoms selected from —NR 5 —, —O—, —S—, —S(O)—, or —SO 2 —, wherein the heterocyclyl or heteroaryl ring may be optionally substituted by one to three R 11 groups;
R 9 is halo;
R 10 is —N(R 16 ) 2 ;
R 11 , R 12 , and R 13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C 1 -C 6 )alkoxy, —R 6 (R 9 ) q , —OR 6 (R 9 ) q , nitro, —SO 2 R 6 , (C 1 -C 6 )alkyl, —C(O)R 10 , —R 4 YR 6 , —CO(O)R 4 , and —CO(O)R 5 , wherein any two R 11 , R 12 or R 13 groups can optionally join to form a 3 to 8 membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring, wherein the heterocyclyl or heteroaryl ring may contain one to three heteroatoms selected from —NR 5 —, —O—, —S—, —S(O)—, or —SO 2 —, and wherein the cycloalkyl, aryl, heterocyclyl or heteroaryl ring may be optionally substituted by one to three R 16 groups;
R 14 and R 15 are independently selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkoxy, —[C(R 6 ) 2 ] r —, —O[C(R 6 ) 2 ] r —, oxo, hydroxyl, halo, —C(O)R 7 , —R 10 , and —CO(O)R 2 , wherein R 14 and R 15 can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyl ring or 4 to 8 membered heterocyclyl ring containing one to three heteroatoms selected from —NR 5 —, —O—, —S—, —S(O)—, or —SO 2 —, wherein the cycloalkyl ring or heterocyclyl ring may be optionally substituted by one to three R 16 groups;
R 16 is independently selected from the group consisting of —H, halo, oxo, hydroxyl, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, —R 6 (R 9 ) q , —OR 6 (R 9 ) q , —N(R 4 ) 2 , —(CH 2 ) r -heterocyclyl, —C(O)OH, —C(O)NH 2 , —R 5 (R 9 ) q , —OR 5 (R 9 ) q , nitro, —SO 2 R 6 , —C(O)R 10 , and —CO(O)R 4 ;
m and n in each instance are independently 0, 1, 2, 3, or 4;
p is independently 0, 1, 2, 3, or 4; and
r and q in each instance are independently 0, 1, 2, 3, or 4.
44 . A compound having the structure of Formula (II):
or a pharmaceutically acceptable salt thereof, wherein:
A is
L 1 and L 2 are [C(R 6 R 6 ′)] q ;
each instance of Q is independently selected from —CH 2 — or —C(═O)—;
W is selected from a bond or O;
R 1 is selected from the group consisting of —H, (C 1 -C 6 )alkyl, —C(O)R 4 , and
R 2 is selected from the group consisting of —H, (C 1 -C 6 )alkyl, —(C 1 -C 6 )alkyl-OR 4 , —(C 1 -C 6 )alkyl-O—(C 1 -C 6 )alkyl, —C(O)R 5 , —(CH 2 ) r NR 7 R 8 , and —(CH 2 ) r N + (R 4 ) 3 ;
R 3 is selected from the group consisting of —H, (C 1 -C 12 )alkyl, —NR 1 R 2 , —OR 5 ,
wherein:
X is a monocyclic or bicyclic (C 5 -C 14 )aryl; Y is selected from a monocyclic or bicyclic (C 2 -C 9 )heterocyclyl or monocylic or bicyclic (C 2 -C 9 )heteroaryl, each having one to three heteroatoms selected from S, N or O; Z is a monocyclic or bicyclic (C 3 -C 8 )cycloalkyl;
R 4 is selected from the group consisting of —H and (C 1 -C 6 )alkyl;
R 5 is selected from the group consisting of (C 1 -C 6 )alkyl, —(CH 2 ) r NR 7 R 8 , and —(CH 2 ) r OR 7 ;
R 6 and R 6 ′ are independently selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkoxy, haloalkyl, —(CH 2 ) r NR 7 R 8 , —C(O)OH, and —C(O)NH 2 , wherein the R 6 and R 6 ′ groups can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyl ring, and wherein the cycloalkyl ring may be optionally substituted by one to three R 11 groups;
R 7 and R 8 are independently selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, —NR 14 R 15 , and —C(O)CH 3 ;
R 9 is halo;
R 10 is —N(R 16 ) 2 ;
R 11 , R 12 , and R 13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C 1 -C 6 )alkoxy, —R 6 (R 9 ) q , —OR 6 (R 9 ) q , nitro, —SO 2 R 6 , (C 1 -C 6 )alkyl, —C(O)R 10 , —R 4 YR 6 , —CO(O)R 4 , and —CO(O)R 5 ;
R 14 and R 15 are independently selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkoxy, —[C(R 6 ) 2 ] n —, —O[C(R 6 ) 2 ] r —, oxo, hydroxyl, halo, —C(O)R 7 , —R 10 , and —CO(O)R 2 ;
R 16 is independently selected from the group consisting of —H, oxo, halo, hydroxyl, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, —R 6 (R 9 ) q , —OR 6 (R 9 ) q , —N(R 4 ) 2 , —(CH 2 ) r -heterocyclyl, —C(O)OH, —C(O)NH 2 , —R 5 (R 9 ) q , —OR 5 (R 9 ) q , nitro, —SO 2 R 6 , —C(O)R 10 , and —CO(O)R 4 ;
m and n in each instance are independently 0, 1, 2, 3, or 4;
p is independently 0, 1, 2, 3, or 4; and
r and q in each instance are independently 0, 1, 2, 3, or 4.
45 . A compound having the structure of Formula (II):
or a pharmaceutically acceptable salt thereof, wherein:
A is
L 1 and L 2 are both (—CH 2 —);
Q is —C(═O)—;
W is O;
R 1 is —H;
R 2 is selected from the group consisting of —H, (C 1 -C 6 )alkyl, —C(O)R 5 , and —(CH 2 ) r NR 7 R 8 ;
R 3 is
wherein X is a monocyclic or bicyclic (C 5 -C 14 )aryl;
R 4 is selected from the group consisting of —H and (C 1 -C 6 )alkyl;
R 5 is selected from the group consisting of (C 1 -C 6 )alkyl, —(CH 2 ) r NR 7 R 8 , and —(CH 2 ) r OR 7 ;
R 6 is selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkoxy, haloalkyl, —(CH 2 ) r NR 7 R 8 , —C(O)OH, and —C(O)NH 2 ;
R 7 and R 8 are independently selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, —NR 14 R 15 , and —C(O)CH 3 ;
R 9 is halo;
R 10 is —N(R 16 ) 2 ;
R 11 , R 12 , and R 13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C 1 -C 6 )alkoxy, —R 6 (R 9 ) q , —OR 6 (R 9 ) q , nitro, SO 2 R 6 , (C 1 -C 6 )alkyl, —C(O)R 10 , —CO(O)R 4 , and —CO(O)R 5 ;
R 14 and R 15 are independently selected from the group consisting of —H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkoxy, —[C(R 6 ) 2 ] r , —O[C(R 6 ) 2 ] r , oxo, hydroxyl, halo, —C(O)R 7 , —R 10 , and —CO(O)R 2 ;
R 16 is independently selected from the group consisting of —H, oxo, halo, hydroxyl, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, —R 6 (R 9 ) q , —OR 6 (R 9 ) q , —N(R 4 ) 2 , —(CH 2 ) r -heterocycle, —C(O)OH, —C(O)NH 2 , —R 5 (R 9 ) q , —OR 5 (R 9 ) q , nitro, —SO 2 R 6 , —C(O)R 10 , and —CO(O)R 4 ;
m and n in each instance are independently 0, 1, or 2;
p is independently 0, 1, or 2; and
r and q in each instance are independently 0, 1, 2, or 3.
46 . A compound having the structure of Formula (II):
or a pharmaceutically acceptable salt thereof, wherein:
A is
L 1 and L 2 are both (—CH 2 —);
Q is —C(═O)—;
W is O;
R 1 is —H;
R 2 is —(CH 2 ) r NR 7 R 8 ;
R 3 is
wherein X is phenyl;
R 7 and R 8 are independently selected from the group consisting of —H and methyl;
R 9 is selected from the group consisting of chloro, bromo, and fluoro;
R 11 is selected from the group consisting of chloro, bromo, and fluoro;
m is 0, 1, or 2; and
r is 1, 2, or 3.
47 . A compound having the structure:
or a pharmaceutically acceptable salt thereof.
48 . A compound having the structure:
or a pharmaceutically acceptable salt thereof.
49 . (canceled)
50 . (canceled)
51 . A compound or a pharmaceutically acceptable salt thereof selected from the group consisting of:
Parent Structure
Chemical Name
4-[(1R)-1- [(1R,2R,5R,10S,13R,14R,17S,19R)- 17-[(3-carboxy-3,3- dimethylpropanoyl)oxy]- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-5-yl]-2- {[(4- chlorophenyl)methyl]amino}ethoxy]- 2,2-dimethyl-4-oxobutanoic acid
4-[(1R)-1- [(1R,2R,5R,10S,13R,14R,17S,19R)- 17-[(3-carboxy-3,3- dimethylpropanoyl)oxy]- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-5-yl]-2- {[(4-chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}ethoxy]- 2,2-dimethyl-4-oxobutanoic acid
4-[(1S)-1- [(1R,2R,5R,10S,13R,14R,17S,19R)- 17-[(3-carboxy-3,3- dimethylpropanoyl)oxy]- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-5-yl]-2- {[(4- chlorophenyl)methyl]amino}ethoxy]- 2,2-dimethyl-4-oxobutanoic acid
4-[(1S)-1- [(1R,2R,5R,10S,13R,14R,17S,19R)- 17-[(3-carboxy-3,3- dimethylpropanoyl)oxy]- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-5-yl]-2- {[(4-chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}ethoxy]- 2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-(2-{[(4- chlorophenyl)methyl]amino}ethyl)- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[2-(benzylamino)ethyl]- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-(2-{[(3- chlorophenyl)methyl]amino}ethyl)- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-(2-{[(3-chloro-2- fluorophenyl)methyl]amino}ethyl)- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-(2-{[1-(4- chlorophenyl)cyclopropyl]amino} ethyl)-1,2,14,18,18-pentamethyl-7- oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-(2-{[(4- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}ethyl)- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-(2-{[1-(4- chlorophenyl)cyclopropyl][2- (dimethylamino)ethyl]amino}ethyl)- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.01′{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-(2-{[(4- chlorophenyl)methyl](methyl)amino} ethyl)-1,2,14,18,18-pentamethyl- 7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,103,13R,14R,17S,19R)- 5-(2-{N-[(4- chlorophenyl)methyl]acetamido} ethyl)-1,2,14,18,18-pentamethyl-7- oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(4- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(4- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(4- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,103,13R,14R,17S,19R)- 5-[(1R)-1-(acetyloxy)-2-{[(4- chlorophenyl)methyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(4- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(4- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-1-(acetyloxy)-2-{[(4- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-1-(acetyloxy)-2-{[(4- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
5- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(4- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-3,3-dimethyl-5- oxopentanoic acid
5- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(4- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-3,3-dimethyl-5- oxopentanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(2- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(2- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-1-(acetyloxy)-2-{[(4- fluorophenyl)methyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, }.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-1-(acetyloxy)-2-{[(4- fluorophenyl)methyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-1-acetoxy-2-((4- fluorobenzyl)(methyl)amino)ethyl)- 1-isopropyl-5a,5b,8,8,11a- pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(4- chlorophenyl)methyl](methyl)amino}- 1-hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- y)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((R)-1-Acetoxy-2-((4- chlorobenzyl)(methyl)amino)ethyl)- 1-isopropyl-5a,5b,8,8,11a- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(4- chlorophenyl)methyl](methyl)amino}- 1-hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-1-Acetoxy-2-(N- (4-chlorobenzyl)acetamido)ethyl)- 1-isopropyl-5a,5b,8,8,11a- pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{N-[(4- chlorophenyl)methyl]acetamido}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-2-(N-(4- Chlorobenzyl)acetamido)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid
4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((R)-2-(N-(4- Chlorobenzyl)acetamido)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid
4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-2-(N-(2- Chlorobenzyl)acetamido)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-1-(acetyloxy)-2-{[(2- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(3- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(3- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(3- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(3- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-1-(acetyloxy)-2-{[(3- chlorophenyl)methyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-1-(acetyloxy)-2-{[(3- chlorophenyl)methyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-1-acetoxy-2-((3- chlorobenzyl)(2- (dimethylamino)ethyl)amino)ethyl)- 1-isopropyl-5a,5b,8,8,11a- pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid
4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((R)-1-acetoxy-2-((3- chlorobenzyl)(2- (dimethylamino)ethyl)amino)ethyl)- 1-isopropyl-5a,5b,8,8,11a- pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid
4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((R)-2-((3- chlorobenzyl)(ethyl)amino)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid
4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-2-((3- Chlorobenzyl)(2- (dimethylamino)ethyl)amino)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid
4- (((3aR,5aR,5bR,7aR,9S,11aR, 11bR,13aS)-3a-((R)-2-((3- Chlorobenzyl)(2- (dimethylamino)ethyl)amino)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2- oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10, 11,11a,11b,12,13,13a- octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid.
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{N-[(3- chlorophenyl)methyl]acetamido}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{N-[(3- chlorophenyl)methyl]acetamido}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((R)-1-acetoxy-2-((2- chlorobenzyl)(2- (dimethylamino)ethyl)amino)ethyl)- 1-isopropyl-5a,5b,8,8,11a- pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid
4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((R)-2-((2- chlorobenzyl)(ethyl)amino)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(2- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(2- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-1-(acetyloxy)-2- (benzylamino)ethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-1-(acetyloxy)-2- (benzylamino)ethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((R)-2-((3-Chloro-2- fluorobenzyl)amino)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid
4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-2-((3-chloro-2- fluorobenzyl)amino)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid.
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(3-chloro-2- fluorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(3-chloro-2- fluorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-1-hydroxy-2-[(propan-2- yl)amino]ethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-(cyclohexylamino)-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5S,10S,13R,14R,17S,19R)- 5-[1-hydroxy-2-(4- methylpiperazin-1-yl)ethyl]- 1,2,14,18,18-pentamethyl-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-(2-{[(4- chlorophenyl)methyl]amino}ethyl)- 1,2,14,18,18-pentamethyl-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5S,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(4- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5S,10S,13R,14R,17S,19R)- 5-[(1S)-2- [(cyclohexylmethyl)amino]-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-(cyclohexylamino)-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-1-hydroxy-2-(1,2,3,4- tetrahydroisoquinolin-2-yl)ethyl]- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-1-hydroxy-2-(1,2,3,4- tetrahydroisoquinolin-2-yl)ethyl]- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,10S,13R,14R,17S,19R)- 5-[(5S)-3-[1-(5-chloropyrimidin-2- yl)cyclopropyl]-2-oxo-1,3- oxazolidin-5-yl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,10S,13R,14R,17S,19R)- 5-[(5R)-3-[1-(5-chloropyrimidin-2- yl)cyclopropyl]-2-oxo-1,3- oxazolidin-5-yl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
5- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(4- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-3,3-dimethyl-5- oxopentanoic acid
4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((R)-2-(3,4- dihydroisoquinolin-2(1H)-yl)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid
4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-2-(3,4- dihydroisoquinolin-2(1H)-yl)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid.
4- (((3aS,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((R)-1-hydroxy-2-(4- methylpiperazin-1-yl)ethyl)-1- isopropyl-5a,5b,8,8,11a- pentamethyl- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid.
4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-(2-((4- chlorobenzyl)amino)ethyl)-1- isopropyl-5a,5b,8,8,11a- pentamethyl- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid
4- (((3aS,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-2- ((cyclohexylmethyl)amino)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid.
4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-2- (cyclohexylamino)-1-hydroxyethyl)- 1-isopropyl-5a,5b,8,8,11a- pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid
4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-2-(benzyl(2- (dimethylamino)ethyl)amino)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-1-(acetyloxy)-2-{[2- (dimethylamino)ethyl][(4- fluorophenyl)methyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-1-(acetyloxy)-2-{[2- (dimethylamino)ethyl][(4- fluorophenyl)methyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
5- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(4- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-3,3-dimethyl-5- oxopentanoic acid
5- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-2-((4- chlorobenzyl)amino)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)- 3,3-dimethyl-5-oxopentanoic acid
4- {[(1R,2R,5R,103,13R,14R,17S,19R)- 5-[(1S)-2-{[(2,4- dichlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{benzyl[2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[2- (dimethylamino)ethyl][(4- fluorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(4- fluorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[2- (dimethylamino)ethyl][(4- fluorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(4- fluorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(2,4- dichlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-[1-(4-chlorophenyl)- N-[2- (dimethylamino)ethyl]formamido]- 1-hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-(2-{[(2- chlorophenyl)methyl]amino}ethyl)- 1,2,14,18,18-pentamethyl-7-oxo-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
2,2-dimethyl-4-oxo-4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 1,2,14,18,18-pentamethyl-7- oxo-5-[2-(phenylformamido)ethyl]- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}butanoic acid
52 . (canceled)
53 . (canceled)
54 . A compound having the structure:
55 . A compound having the structure:
56 . (canceled)
57 . (canceled)
58 . A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
59 . The composition of claim 58 , wherein the compound is present in an amorphous form.
60 . The composition of claim 58 , wherein the composition is in a tablet form.
61 . The composition of claim 58 , wherein the compound is present as a spray dried dispersion.
62 . A method of treating an HIV infection in a subject comprising administering to the subject a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
63 . A method of treating an HIV infection in a subject comprising administering to the subject a pharmaceutical composition comprising a compound having the structure:
or a pharmaceutically acceptable salt thereof.
64 . A method of preventing an HIV infection in a subject at risk for developing an HIV infection, comprising administering to the subject a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
65 . A method of preventing an HIV infection in a subject at risk for developing an HIV infection, comprising administering to the subject a pharmaceutical composition comprising a compound having the structure:
or a pharmaceutically acceptable salt thereof.
66 . The method of claim 62 , further comprising administration of one or more additional agents active against HIV.
67 . The method of claim 66 , wherein said one or more additional agents active against HIV is selected from the group consisting of zidovudine, didanosine, lamivudine, zalcitabine, abacavir, stavudine, adefovir, adefovir dipivoxil, fozivudine, todoxil, emtricitabine, alovudine, amdoxovir, elvucitabine, nevirapine, delavirdine, efavirenz, loviride, immunocal, oltipraz, capravirine, lersivirine, GSK2248761, TMC-278, TMC-125, etravirine, saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, brecanavir, darunavir, atazanavir, tipranavir, palinavir, lasinavir, enfuvirtide, T-20, T-1249, PRO-542, PRO-140, TNX-355, BMS-806, BMS-663068 and BMS-626529, 5-Helix, raltegravir, elvitegravir, GSK1349572, GSK1265744, vicriviroc (Sch-C), Sch-D, TAK779, maraviroc, TAK449, didanosine, tenofovir, lopinavir, and darunavir.
68 .- 130 . (canceled)Join the waitlist — get patent alerts
Track US2016120878A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.